Shai Jalfin Image

Shai Jalfin

is the Senior Vice President of Morningside’s patent division. Shai has helped numerous Fortune 500 clients and international patent firms streamline their formalities processes, reduce costs, and achieve more with their IP budgets. With over 10 years’ experience in foreign patent filing and EP validation, Shai has an extensive experience creating customized, cost-effective solutions for multinational filing.

Recent Articles by Shai Jalfin

6 Years Later: The Effects of the Mayo Decision on Diagnostic Methods

2018 celebrates the six-year anniversary of one of the most important Supreme Court decisions of the modern era. On March 20, 2012, the Court handed down its ruling in Mayo v. Prometheus Laboratories. The decision was understood immediately to be a break from the immediate past, a product of the Court’s intention to clarify patent eligibility for a new era of biotech, pharma, and life science technologies. The Court hoped it would help clarify eligibility issues raised by new technologies that the drafters of Title 35 § 101, 102, and 103 hadn’t envisioned, but it’s done the opposite. Six years later, eligibility is harder to discern than ever, especially for diagnostic method claims.

The Good, Bad and Ugly of Cross-Licensing Your Technology Patents

A cross-licensing patent agreement is a contract between at least two parties that grants mutual rights to both parties’ intellectual property. The agreement may be a private one between two specific companies or a small consortium of companies. Or it may be a public agreement such as a patent pool, in which IP management is shared amongst a relatively large group of patent holders who share patents. Patent pools are typically industry-based, and companies active in the sector are free to join the pool.